Showing 4501-4510 of 9774 results for "".
- Alphaeon Launches Social Commerce Store for Physician Specialistshttps://practicaldermatology.com/news/alphaeon-launches-social-commerce-store-for-physician-specialists/2458876/ALPHAEON Corporation launched ShoutMD 3.0. ShoutMD is a unique professional and social network that allows board certified physician specialists to share insights, start discussions, and collaborate with their peers with the goal of improving patient experiences and outcomes, according to the com
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
- FDA Issues Consumer Update about Injectable Skin Lightening Productshttps://practicaldermatology.com/news/fda-issues-consumer-update-about-injectable-skin-lightening-products/2458879/A consumer update from the FDA warns that injectable skin lightening products are unapproved, untested drugs that could potentially cause harm. The FDA adds that it has not approved any injectable drugs for skin whitening or lightening. “These products pose a potentially significant
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- FDA Approves Odomzo for Locally Advanced BCChttps://practicaldermatology.com/news/fda-approves-odomzo-sonidegib-for-locally-advanced-bcc/2458903/The FDA approved Novartis’ Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radi
- Cynosure's SculpSure Receives Expanded FDA Clearance for Lipolysis of the Abdomenhttps://practicaldermatology.com/news/cynosures-sculpsure-receives-expanded-fda-clearance-for-lipolysis-of-the-abdomen/2458914/Cynosure, Inc. has received 510(k) clearance from the FDA to market SculpSure™ for non-invasive lipolysis of the abdomen. In May, the FDA cleared SculpSure for non-invasive lipolysis of the flanks. SculpSure is a safe, clinically proven treatment designed to reduce fat non-invasivel
- LEO Pharma Inc. Announces New Vice President of Saleshttps://practicaldermatology.com/news/leo-pharma-inc-announces-new-vice-president-of-sales/2458915/Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales. "Mitch is a welcomed addition to our team. He is an energetic sales leader and strategist with proven results in the pharmaceutical industry," stated Barbara Osborne, President & CEO, LEO U.S. Mr. Jo
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- ASDS: Laser Hair Removal On the Risehttps://practicaldermatology.com/news/asds-laser-hair-removal-on-the-rise/2458918/More patients are seeking laser treatments to permanently remove unwanted hair, a new American Society for Dermatologic Surgery (ASDS) survey shows. About 633,000 laser hair removal procedures were performed by ASDS members last year – a 27 percent increase from 2013 and a 51 percen
- Galderma Introduces ASPIRE Loyalty Program for the Aesthetic Industryhttps://practicaldermatology.com/news/galderma-introduces-aspire-loyalty-program-for-the-aesthetic-industry/2458936/Galderma launched ASPIRE Galderma Rewards, a new loyalty program for its aesthetic brands. ASPIRE is unique in that it serves both both US healthcare professionals and consumers in one integrated program. ASPIRE rewards its members with significant savings across the entire aesthetic prod